Characteristics and treatment preferences of individuals with opioid use disorder seeking to transition from buprenorphine to extended-release naltrexone in a residential setting

被引:1
|
作者
Mannelli, Paolo [1 ]
Douaihy, Antoine B. [2 ]
Akerman, Sarah C. [3 ]
Legedza, Anna [3 ]
Fratantonio, James [3 ]
Zavod, Abigail [3 ]
Sullivan, Maria A. [3 ,4 ]
机构
[1] Duke Univ, Med Ctr, Dept Psychiat & Behav Sci, 3074,2213 Elba St,Ste 156, Durham, NC 27705 USA
[2] Univ Pittsburgh, Sch Med, Dept Psychiat, Pittsburgh, PA USA
[3] Alkermes Inc, Waltham, MA USA
[4] Columbia Univ, Dept Psychiat, New York, NY USA
来源
AMERICAN JOURNAL ON ADDICTIONS | 2022年 / 31卷 / 02期
关键词
D O I
10.1111/ajad.13264
中图分类号
R194 [卫生标准、卫生检查、医药管理];
学科分类号
摘要
Background and Objectives Treatment for individuals receiving medication for opioid use disorder (MOUD) should follow an informed patient-centered approach. To better support patient autonomy in the decision-making process, clinicians should be aware of patient preferences and be prepared to educate and assist patients in transitioning from one MOUD to another, when clinically indicated. This posthoc analysis describes the characteristics of clinical trial participants (NCT02696434) with a history of opioid use disorder (OUD) seeking to transition from buprenorphine (BUP) to extended-release naltrexone (XR-NTX). Methods The posthoc analysis included adults with OUD currently receiving BUP (<= 8 mg/day) and seeking transition to XR-NTX (N = 101) in a residential setting. Baseline participant characteristics and OUD treatment history were reviewed. All patients completed a screening questionnaire that asked about their reasons for seeking transition to XR-NTX and for choosing BUP. Results The most common reasons for initiating a transition to XR-NTX were "Seeking to be opioid-free" (63.4%) and "Tired of daily pill taking" (25.7%). Positive predictors of transition included a more extensive BUP treatment history and a history of prescription opioid abuse. Most participants stated they were not aware of XR-NTX as a treatment option when initiating BUP (78.2%). Discussions and Conclusions Patients' reasons for seeking XR-NTX transition, more extensive BUP treatment history, and a history of prescription opioid abuse, may positively predict outcomes. Scientific Significance These findings may assist clinicians in optimizing outcomes of the BUP to XR-NTX transition and supporting patients to make better informed MOUD decisions.
引用
收藏
页码:142 / 147
页数:6
相关论文
共 50 条
  • [21] Personal recovery among people with opioid use disorder during treatment with extended-release naltrexone
    Marciuch, Anne
    Birkeland, Bente
    Benth, Jurate Saltyte
    Solli, Kristin Klemmetsby
    Tanum, Lars
    Mathisen, Ida
    Weimand, Bente
    HELIYON, 2023, 9 (07)
  • [22] Case series: Voluntary discontinuation of sublingual buprenorphine treatment for opioid use disorder using extended-release buprenorphine
    Rodriguez, Claudia P.
    Suzuki, Joji
    AMERICAN JOURNAL ON ADDICTIONS, 2023, 32 (03): : 314 - 317
  • [23] Reduced cigarette smoking during injectable extended-release naltrexone treatment for opioid use disorder
    Wang An-Li
    Shi Zhenhao
    Elman, Igor
    Langleben, Daniel D.
    AMERICAN JOURNAL OF DRUG AND ALCOHOL ABUSE, 2020, 46 (04): : 472 - 477
  • [24] Depression and Suicidal Ideation in Adults With Opioid Use Disorder Treated With Buprenorphine-Naloxone Versus Extended-Release Naltrexone
    Rizk, Mina
    Stanley, Barbara
    Choo, Tse-Hwei
    Pavilcova, Martina
    Scodes, Jennifer
    Campbell, Aimee
    Nunes, Edward
    Rotrosen, John
    BIOLOGICAL PSYCHIATRY, 2020, 87 (09) : S268 - S269
  • [25] Extended-release naltrexone for opioid use disorder started during or following incarceration
    Lincoln, Thomas
    Johnson, Benjamin D.
    McCarthy, Patrick
    Alexander, Ellen
    JOURNAL OF SUBSTANCE ABUSE TREATMENT, 2018, 85 : 97 - 100
  • [26] A Comparison of Neuropsychological Functioning between Patients With Opioid Use Disorders on Extended-Release Naltrexone and Buprenorphine
    Castillo, Felipe
    Campbell, Aimee
    Choo, Tse-Hwei
    Pavlicova, Martina
    Rotrosen, John
    Selzer, Jeffrey A.
    Nunes, Edward, V
    DRUG AND ALCOHOL DEPENDENCE, 2025, 267
  • [27] Extended-Release Injection vs Sublingual Buprenorphine for Opioid Use Disorder With Fentanyl Use
    Nunes, Edward V.
    Comer, Sandra D.
    Lofwall, Michelle R.
    Walsh, Sharon L.
    Peterson, Stefan
    Tiberg, Fredrik
    Hjelmstrom, Peter
    Budilovsky-Kelley, Natalie R.
    JAMA NETWORK OPEN, 2024, 7 (06) : e2417377
  • [28] Trajectory classes of opioid use among individuals in a randomized controlled trial comparing extended-release naltrexone and buprenorphine-naloxone
    Ruglass, Lesia M.
    Scodes, Jennifer
    Pavlicova, Martina
    Campbell, Aimee N. C.
    Fitzpatrick, Skye
    Barbosa-Leiker, Celestina
    Burlew, Kathleen
    Greenfield, Shelly F.
    Rotrosen, John
    Nunes, Edward V., Jr.
    DRUG AND ALCOHOL DEPENDENCE, 2019, 205
  • [29] The relationship between reincarceration and treatment of opioid use disorder with extended-release naltrexone among persons with HIV
    Parchinski, Kaley
    Di Paola, Angela
    Wilson, Allison P.
    Springer, Sandra A.
    DRUG AND ALCOHOL DEPENDENCE REPORTS, 2023, 7
  • [30] No Increase in Chronic Pain Among Opioid-Dependent individuals Randomized to Treatment With Extended-Release Naltrexone or Buprenorphine-Naloxone
    Latif, Zill-e-Huma
    Solli, Kristin
    Opheim, Arild
    Kunoe, Nikolaj
    Benth, Jurate
    Krajci, Peter
    Tanum, Lars
    NEUROPSYCHOPHARMACOLOGY, 2018, 43 : S509 - S509